32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screened Final sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024 Final data from our first neoadjuvant breast cancer study... Read More

INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada , Europe and Australia SHELTON, Conn. , Jan. 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and... Read More

The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients Seven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple... Read More

Enrollment is ongoing and seven sites in Switzerland have been activated SHELTON, Conn. and BERN, Switzerland , Dec. 12, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc . ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase... Read More

SHELTON, Conn. , Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has entered into a securities purchase agreement with a... Read More

Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S.,... Read More

First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn. , Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system... Read More

SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, today announced that its Phase 3 trial has been selected for... Read More

Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone The endpoint is the change in pathological complete response rates SHELTON, Conn. and BERN, Switzerland , Oct. 31, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc . ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery... Read More

SHELTON, Conn. , Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender , Founder, President and Chief Executive Officer, will present a corporate... Read More

First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn. , Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc.... Read More

Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn. , July 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc . ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer... Read More

SHELTON, Conn. , May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin , J.D., MPH, to the Intensity Board of... Read More

SHELTON, Conn. , May 10, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company executed a collaboration agreement with The Swiss... Read More

INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025 SHELTON, Conn. , May 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery... Read More

SHELTON, Conn. , April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender , Founder, President and Chief Executive Officer, will present a corporate... Read More

INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer Year-end cash and investments of $14.8 million expected to fund operations through the end of Q1 '25 Focusing on clinical operational and regulatory progress for a new technology to treat cancer Multiple clinical opportunities in cancer types having high unmet medical need Upcoming clinical milestones SHELTON,... Read More

SHELTON, Conn. , March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender , Founder, President and Chief Executive Officer, will participate in a... Read More

SHELTON, Conn. , Feb. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Lewis H. Bender , President and Chief Executive Officer, will present a company overview... Read More

FDA provides "Study May Proceed" letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn. , Jan. 3, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer... Read More

Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn. , Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies... Read More

INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single injection of INT230-6 can induce up to >95% necrosis of a tumor INT230-6 demonstrated an increase in CD4 T-cells and NK cells within tumors Gene expression profiling revealed treatment effect of up-regulation of immune pathways... Read More

WESTPORT, Conn. , Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer... Read More

Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society ("CTOS"), demonstrating 93% disease control rate in patients on monotherapy and survival extension of nearly 15 months vs. synthetic control group Received Orphan Drug Designation for the three components of INT230-6 for the treatment of soft tissue sarcoma Closed upsized IPO and full... Read More

The disease control rate for subjects in the monotherapy was 93% for patients who received at least one dose of INT230-6 INT230-6 extended survival in refractory soft tissue sarcoma subjects by nearly 15 months when compared to a synthetic control group In the study, INT230-6 was found to have a favorable safety profile and be well tolerated, with approximately 90% adverse events being grade 1 or 2 WESTPORT, Conn. , Nov. 2,... Read More

WESTPORT, Conn. , Sept. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that the US Food and Drug Administration's Office of Orphan Products... Read More

WESTPORT, Conn. , Sept. 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Lewis H. Bender , President and Chief Executive Officer, will present a company overview at... Read More